Normalized whole brain volume change over 5 years using an SPM pipeline. by Renxin Chu (5169857)

Transition of mean retinal sensitivity by each pattern of abnormal FAF during the 5 years. by Ari Shinojima (833477)

“…The speckled FAF pattern at the 5th year had the lowest mean retinal sensitivity. …”

Functional analysis of miR-142-3p upregulation on invasiveness, viability and size of MDA-MB-231, MDA-MB-468 and MCF-7 breast cancer cells. by Alexander Schwickert (835514)

“…(f, h) pseudo-three-dimensional representations of the phase images in e, g correspond to the projection of the cell thickness. (i) cell volume V of n = 251 miR-142-3p transfected cells appears significantly decreased in comparison to the volume of n = 172 control cells; Data are mean ± SEM, *P<0.05, ***P<0.001.…”

Percentage of disturbance observations in which a particular disturbance intensity was observed, per species, drone type and drone flight altitude. by Estefania Velilla (22566709)

S5 Fig - by Kristen L. Lokken-Toyli (9455263)

IC₅₀ of indole alkaloid against alpha-glucosidase [26]. by Atikarn Janthongkaw (17020498)

Mean persistence (±SE) of GO and GO-GA NPs on <i>Callosobruchus maculatus.</i> by Huda H. Elbehery (22492996)

Decreased retinal cell density is associated with increased cell death in <i>Lrp2</i>^{<i>FoxG1</i>.<i>cre-KO</i>} mutant eyes. by Olivier Cases (760028)

Concentration of DRS-B2 and [W/F]³-DRS-B2 that inhibits 50% of cell growth (GI₅₀) extracted from Fig 12. by Célia Dos Santos (306471)

Variable importance metric as measured by mean decrease in gini index (standardized between 0 and 100) for internalizing problem behavior, based on random forest with the number of variables sampled at each split (mtry) = 5, and number of trees (ntree) = 100 fitted on the entire dataset. by Samrachana Adhikari (7818143)

Adverse events in low-dose naltrexone arm. by Judith I. Tsui (5983160)

Subjects:

CONSORT flow diagram. by Judith I. Tsui (5983160)

Subjects:

Adverse events in placebo arm. by Judith I. Tsui (5983160)

Subjects:

Medication tolerability, discontinuations, adherence over the 8-week study period. by Judith I. Tsui (5983160)

Subjects:

Adverse events in gabapentin arm. by Judith I. Tsui (5983160)

Subjects:

Medication satisfaction over 8-week study medication period. by Judith I. Tsui (5983160)

Subjects:

Main results: Changes in primary and secondary outcomes from baseline to 8 weeks in the PETER PAIN trial. by Judith I. Tsui (5983160)

Subjects:

Baseline characteristics of PETER PAIN study participants: People with HIV, chronic pain, and heavy alcohol use (n = 45). by Judith I. Tsui (5983160)

Subjects:

IL-17A promotes RANKL-stimulated osteoclastogenesis. by Hao Tang (44155)

Motor activity (cm) inside the chamber for day 1 and 5. by Silvia Fuentes (4759686)